Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix (NASDAQ:NBTX) reported FY 2023 GAAP EPS of $(1.17), surpassing the $(1.66) estimate, and sales of $39.323M, exceeding the $13.680M estimate. This represents a significant improvement over the previous year, with a 32.37% decrease in losses per share and a 681.30% increase in sales.
April 24, 2024 | 9:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nanobiotix reported a significant beat on both EPS and sales estimates for FY 2023, with EPS at $(1.17) against a $(1.66) estimate and sales reaching $39.323M, far exceeding the $13.680M forecast.
Nanobiotix's significant outperformance in both earnings per share and sales compared to analyst estimates indicates strong operational efficiency and market demand for its products. The substantial year-over-year growth in sales and reduction in losses per share suggest improved financial health and operational success, likely leading to positive investor sentiment and potential short-term stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100